wo new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:
- Monthly formulary amendments – July 2026
- Monthly horizon scanning – August 2026
Category: Uncategorized
Formulary amendments July 2026 & horizon scanning August 2026
Formulary assessment – Clascoterone 10 mg/g cream
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
The Formulary Assessment tool for Clascoterone 10 mg/g cream can be accessed here
Great North Pharmacy Research Collaborative 2025
The Great North Pharmacy Research Collaborative conference 2025 is taking place on Friday 18th July.
RDTC are attending as always, and this year we’re bringing several posters:
- Analysis of GLP-1 medication Yellow Card reports submitted in the Northern and Yorkshire region in 2024-2025
- Uptake of NICE TAs in the eligible populations
- Using data analysis to identify a ‘medicines roadmap’ to support the uptake of electronic repeat dispensing
We’re also running a breakout session on Deprivation in the North and the effect on prescribing analysis. This will run during the second of the two breakout session slots, and we look forward to seeing you there.
We also have team members supporting the foundation trainee pharmacist workshop on sustaining the future workshop, and helping with assessing poster submissions.
We look forward to seeing you on the day, please come and say hello!
Top 50 expenditure report updated
This report looks at the top 50 BNF sections and drugs, with a focus on cost growth and item growth.
To access the latest report, visit Top 50 BNF Sections and Drugs.
RDTC at Clinical Pharmacy Congress North
We’re pleased to confirm that RDTC will be at the inaugural CPC North this November!
The event takes place in Manchester on November 3rd and 4th. More details are available on the Pharmacy Congress website, and registration is still open.
You can find us at stand A23, where we’ll be ready to chat about our work and what we can do for you. We’ll have examples of recent work to show how we can support your medicines optimisation and strategic activities, together with what we have planned for the upcoming year.
Monica Mason, Head of Prescribing Support at the RDTC, will be joining the Chairs of GMMMG Professor Charlotte Skitterall and Claire Vaughan at 9:30am on Friday morning in the Clinical Theatre in a session titled “Optimisation of medicines opportunities in Greater Manchester”. Find full details on the CPC North Programme.
We look forward to seeing you there!
Budget impact of methylphenidate modified release tablet choice
The latest in the RDTC’s prescribing bulletin series covers methylphenidate, and highlights the difference in cost between bioequivalent methylphenidate modified release (MR) tablets. It considers the budget impact of MR tablet choice and shows the yearly primary care spend on all methylphenidate XL tablets, and the proportion of this spend on each of the available brands.
This bulletin, and our others, are available from the Prescribing Bulletins page.
Monthly formulary amendments – March 2023
A Monthly Formulary Amendments document covering guidance and alerts published in March 2023 is now available.
The purpose of the document is to support consistent decision making by APCs. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
This document is available alongside previous editions on the formulary amendments page.